Please disable your Ad Blocker to better interact with this website.

Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
News

New Study Finds Hydroxychloroquine Reduced COVID-19 Deaths

Will this presidential election be the most important in American history?

A new study found the use of hydroxychloroquine was associated with about a 50 percent reduction in COVID-19 mortality.

The research study conducted by a group at the Henry Ford Health System in Michigan reported 13 percent of patients died who received hydroxychloroquine as compared to 26 percent that didn’t receive the drug.

The study, “Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19,” was published in The International Journal of Infectious Diseases.

Sharyl Attkisson summarized the results in a table.

https://twitter.com/SharylAttkisson/status/1279029696261390336

The study result differed with other recent studies on hydroxychloroquine and one of the researchers pointed out one reason is the importance of using the drug early in treatment.

Dr. Marcus Zervos said, “For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with Covid.”

NBC News Detroit WDIV reported on the Henry Ford Health System study.

Treating COVID-19 patients with hydroxychloroquine became a controversy after President Trump made positive statements about the drug.

The FDA recently removed the emergency use authorization for hydroxychloroquine for COVID-19 in hospitals because the agency felt the risk of using the drug was greater than the benefits.

CNN’s bias was evident in its tweet about the study where the words “surprising” and “controversial” were used.

CNN has consistently attacked the use of the drug in previous reports and they continued the trend during an interview with a network medical expert.

Confusion about hydroxychloroquine was exacerbated when a study published in The Lancet concluded its use was associated with an increase in deaths.

However, the study was retracted because the co-author, Sapan Desai, refused to release the underlying data collected by his company Surgisphere Corporation to the medical journal after concerns were expressed about its accuracy by outside scientists.

The Lancet said in a statement:

Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process.

Another study by Dr. Zev Zelenko also showed encouraging results with a combination of hydroxychloroquine, Azithromycin and Zinc.

He found that, “hospitalization of treated patients were 84% less than in the untreated group. One patient (0.7%) died in the treatment group versus 13 patients (3.5%) in the untreated group.”

Dr. Zelenko made his research available on Preprints, a website that posts research that has not yet been peer reviewed.

https://twitter.com/zev_dr/status/1279010904911249409?s=20

The new study showed encouraging results and more research is necessary to make the final call on hydroxychloroquine as an effective treatment for COVID-19.

However, emotion surrounding hydroxychloroquine is so high that YouTube removed content discussing its use.

In fact, my Newsmax TV interview on hydroxychloroquine on The Chris Salcedo Show was removed from my YouTube channel.

My appeal was also rejected.

Unfortunately, the politicization of the drug just because President Trump supported it will continue to cloud the research.

In the end, Americans will suffer and potentially die because politics is poisoning the scientific method.

Tom Borelli

Dr. Tom Borelli is a Newsmax TV contributor and radio commentator addressing political issues from a conservative grassroots perspective. As a columnist, he has written for The Washington Times and authored articles for Newsmax Magazine, Newsmax Insider and previously was a co-host with his wife Deneen Borelli on the SiriusXM Patriot channel. Dr. Borelli appeared on numerous television programs, including the highly ranked Fox News Channel’s “The O’Reilly Factor,” “Hannity,” “The Kelly File," and "America’s News Headquarters." He has also appeared on Fox Business Network’s “Making Money with Charles Payne” and “After the Bell” as well as TheBlaze TV’s "The Glenn Beck Program" and "Dana!" Prior to working for public policy organizations, Dr. Borelli was a managing partner with the investment advisory firm of Action Fund Management, LLC and a portfolio manager for the Free Enterprise Action Fund (FEAF) where he used shareholder activism to challenge corporations that sought to profit from the growth of government. During his 25 years with the Altria Group, Inc., he built a foundation in public policy and issues management, drawing from diverse experiences ranging from basic research to corporate affairs. Dr. Borelli served as science fellow for the U.S. House of Representatives' Committee on Science, Space, and Technology during the 100th Congress. Dr. Borelli has also published scientific papers on interferon and human leukemia.

Related Articles